A common heart drug has shown promise to delay the onset of Huntington's disease -- a progressive and inherited brain ...

Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...

New therapy for Huntington’s disease ‘may slow progression’ - There are thought to be around 7,000 people living with ...

A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...

Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.

PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...

The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

A roundup of significant health updates globally includes Sanofi's major investment in China, New Zealand suspending poultry ...

RBC Capital has upgraded PTC Therapeutics (PTCT) to outperform from sector perform on the company’s deal with Novartis (NVS) for its Huntington’s disease program. Read more here.

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa Health Care researchers.